The trial marked changes in pharmacodynamics (PD) biomarkers and maximal reductions in factor XI (FXI) antigen and activity > 90% and an aPTT (thromboplastin time) increase of > 100% at the ...
The Phase I trial of the company’s SRSD107 siRNA therapy found the treatment to be safe and well tolerated as part of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback